1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Kleo Brings Small-Molecule Approach To IO With Three Technological Applications

 
• By Joseph Haas

Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.

Emerging Company Profile Regular column feature image Version 2

Kleo Pharmaceuticals Inc. thinks it can complement biological therapy in immuno-oncology and perhaps even supplant some of those therapeutics with a versatile, modular small molecule technology platform for developing drugs that will offer enhanced efficacy and better safety.

Partnered with PeptiDream Inc. and claiming Biohaven Pharmaceutical Holding Co. Ltd. as an early investor, the New Haven,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer